Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan clinical oncology group study JCOG0602

Japanese Journal of Clinical Oncology

Volumn 38, Issue 1, 2008, Pages 74-77

  Onda, Takashi ^a   Matsumoto, Koji ^b   Shibata, Taro ^c   Sato, Akihiro ^c   Fukuda, Haruhiko ^c   Konishi, Ikuo ^d   Kamura, Toshiharu ^e   Yoshikawa, Hiroyuki ^f  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d SHINSHU UNIVERSITY   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Interval debulking surgery; Neoadjuvant therapy; Ovarian neoplasms; Primary debulking surgery

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 39049102018     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym145     Document Type: Article

References (10)

1. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269-74.
2. Dauplat J, Le Bouedec G, Pomel C, Scherer C. Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 2000; 19:42-8.
3. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-50.
4. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996;17:393-6.
5. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999;72:93-9.
6. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
7. Kayikçioǧlu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001; 11:466-70.
8. Vergote I, de Wever I, Tjalma W, Van Gramberen M, Decloedt J, Van Dam P. Interval debulking surgery: An alternative for primary surgical debulking? Semin Surg Oncol 2000; 19:49-53.
9. Onda T, Kamura. T, Ishizuka N, Katsumata N, Fukuda H, Yoshikawa H. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Jpn J Clin Oncol 2004;34:43-5.
10. Onda T, Kamura T, Hirakawa T, Kuzuya K, Hatae M, Iwasaka T, et al. Feasibility study of neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study JCOG0206 (Abstract 15020). J Clin Oncol, ASCO Annual Meeting Proceedings 2006;24:15020